AudioCure

AudioCure Pharma specializes in the preclinical and clinical development of small molecules for the treatment of audiological and neurodegenerative diseases like sudden hearing loss, tinnitus, Parkinson’s and Alzheimer’s disease. In a first step the company focuses on sudden hearing loss.

Our compounds AC102 and AC002 have shown excellent efficacy in different animal models for the above-mentioned indications. Consequently, AudioCure is on its way to perform formal preclinical tests and to move AC102 into first-in-man testing.

Management

Prof. Dr. Hans Rommelspacher, CSO

Dr. Reimar Schlingensiepen, CEO

Pressemeldungen

AudioCure Pharma GmbH secures funding of about EUR 9 million for the further development of their lead candidate, AC102, in hearing loss

AudioCure, a pharmaceutical R&D company headquartered in Germany, announces today that it has secured an A-round of about EUR 9 million from MED-EL, HTGF and private investors. MED-EL receives exclusive licensing rights and shares while existing investors increase their shares. AudioCure will use the funding to…
Read

High-Tech Gründerfonds and Business Angel Invest in AudioCure Pharma GmbH Drug Development

AudioCure Pharma concentrates on the clinical development of drug candidates in neurodegenerative disease indications with a high unmet medical need. The lead candidate is a small molecule compound for the treatment of acute and chronic hearing impairments via local, regenerative therapy of the damaged nerve cells in…
Read

Info & Contact

Prof. Dr. Hans Rommelspacher
Web:
audiocure.de

Address

Schlegelstr. 9
10115 Berlin

In portfolio

20. Apr 2012